Table 3.
E | CIP | CTR | CX | G | COT | CD | AMP | A/s | PIT | IPM | AK | VA | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CONS | 53.4 | 15.1 | 19.7 | 24.4 | 13.9 | – | 37.2 | – | 27.9 | 25.5 | 18.6 | 13.9 | 6.9 |
S. aureus | 47.8 | 13 | 17.3 | 30.4 | 19.5 | – | 26 | – | 34.7 | 39.13 | 15.2 | 17.3 | 4.3 |
P. aeruginosa | – | 33.3 | 16.6 | – | 50 | 100 | – | 100 | – | – | – | 00 | – |
Enterobacter species | – | 50 | 00 | – | 25 | 100 | – | 100 | – | – | – | 00 | – |
E. coli | – | 33.3 | 100 | – | 66.6 | 100 | – | 100 | – | – | – | 33.3 | – |
Figures depict %, – not tested, P penicillin, E erythromycin, CIP ciprofloxacin, CTR ceftriaxone, C chloramphenicol, OX oxacillin, CZ cefazolin, G gentamicin, CN cephalexin, COT cotrimoxazole, AMP ampicillin, AZM azithromycin, AMC amoxy-clavulanic acid, AK amikacin